Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07163793 · ClinicalTrials.gov registry record · Phase 2

Pilot Study of Reduced Venetoclax Exposure

A Phase 2 study of Acute Myeloid Leukemia in Remission, sponsored by Northwell Health.

Recruiting
Registry status
Phase 2
Development phase
41
Enrollment target
1
Study location

NCT07163793: Recruiting Phase 2 study of Acute Myeloid Leukemia in Remission, sponsored by Northwell Health.

NCT07163793 is a Phase 2 study of Acute Myeloid Leukemia in Remission that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 41 participants, below the 65-participant average among 11 other Acute Myeloid Leukemia in Remission trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07163793, a Phase 2 study of Acute Myeloid Leukemia in Remission, is actively recruiting participants, sponsored by Northwell Health.

RECRUITING
Registry status
Phase 2
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

Pilot Study of Reduced Venetoclax Exposure

Primary Outcome

Tolerability rate defined as the proportion of patients who do not experience grade 4 neutropenia (per the CTCAE v5.0) for over 7 continuous days within the first three cycles of maintenance therapy (90 days). Patient will be evaluated on Day 1 of each cycle. Laboratory studies of prior cycle will be reviewed on that day to identify if patient had \>7 continuous days of cytopenia.

Conditions Studied

Acute Myeloid Leukemia in Remission

Interventions

  • DRUG Venetoclax
  • DRUG Azacitidine
  • DRUG Decitabine

Study Locations (1)

New York

  • Zuckerberg Cancer Center - New Hyde Park

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2024-10-07
Est. Completion 2028-10
Phase Phase 2
Northwell Health

370 total trials

What NCT07163793 shows while recruiting

NCT07163793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 65-participant average among 11 other Acute Myeloid Leukemia in Remission trials with a reported enrollment target (37% lower).

The record links to 1 condition, with Acute Myeloid Leukemia in Remission appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT07163793 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT07163793 about?

NCT07163793 is a clinical study titled "Pilot Study of Reduced Venetoclax Exposure". Pilot Study of Reduced Venetoclax Exposure

What is the current status of trial NCT07163793?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2024-10-07. Estimated completion is 2028-10.

What conditions does trial NCT07163793 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia in Remission.

What interventions are being tested in trial NCT07163793?

The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Decitabine (DRUG).

Who is sponsoring clinical trial NCT07163793?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07163793 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia in Remission

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07163793's enrollment target sits among peer trials

41 5th of 11 higher than 7 of 11 other Acute Myeloid Leukemia in Remission trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia in Remission trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03449238 · 41 participants · Phase 1

    Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

  • NCT03900793 · 41 participants · Phase 1

    Losartan + Sunitinib in Treatment of Osteosarcoma

  • NCT04082520 · 41 participants · Phase 2

    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

  • NCT04220190 · 41 participants · Phase 2

    RAPA-501 Therapy for ALS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07163793

Source: ClinicalTrials.gov NCT07163793, the US trial registry maintained by the National Library of Medicine. NCT07163793 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.